CORDIS
EU research results

CORDIS

English EN

Combatting Bacterial Resistance in Europe

Objective

The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified by the World Health Organisation (WHO), and subject of numerous national and international government activities, including the Trans-Atlantic Task Force on Antimicrobial Resistance established by the US and EU presidencies. The estimated costs of ARB are around € 1.5 Billion per year in Europe, with an estimated 25,000 deaths (European Center for Disease prevention and Control/European Medicines Agency “time to react”). While the threat of antimicrobial resistance is growing, so are the challenges to bringing forward new therapeutic options for patients infected with resistant organisms. There is a need for a better understanding of how antimicrobial resistance is evolving globally, of what novel molecular mechanisms can be exploited as new forms of antimicrobial therapy and of how to more efficiently develop new treatments so they can be more rapidly brought to patients in need.
The over-arching concept of New Drugs for Bad Bugs (ND4BB) is to create an innovative public-private collaborative partnership that will positively impact all aspects of ARB through the discovery and development of novel agents for the treatment, prevention and management of patients with bacterial infections. COMBACTE is one of the first projects to be launched under this programme with the aim of developing a broad European network of fully capable and Good Clinical Practice (GCP) compliant clinical investigation sites to execute clinical trials enabling the registration of novel agents to be used in the treatment of patients with bacterial infections. The growth and application of the network will be supported with robust microbiologic surveillance data and clinical epidemiologic data. To reduce the time and or cost of clinical development, novel clinical trial designs will be outlined and supported through analysis of publically available and consortium-shared non-clinical and clinical data. In addition to executing the initial set of clinical trials, investigations of patient and pathogen-related biomarkers and the logistical and decision making impact of rapid diagnostics will be conducted.

Coordinator

ASTRAZENECA AB

Address

Vastra Maelarhamnen
151 85 Sodertaelje

Sweden

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Principal Investigator

Hasan Jafri (Senior Director, Clinical Research and Development)

Administrative Contact

Eva Lindgren (Senior Director)

Participants (36)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Netherlands

EU Contribution

€ 37 874 402

CLINIQUES UNIVERSITAIRES SAINT-LUC

Belgium

EU Contribution

€ 719 243

KLINIKUM DER UNIVERSITAET ZU KOELN

Germany

EU Contribution

€ 1 144 731

Centre hospitalier universitaire de Limoges

France

EU Contribution

€ 45 417 661

FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA

Spain

EU Contribution

€ 862 572

CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE BESANCON

France

EU Contribution

€ 4 380

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH

Germany

EU Contribution

€ 1 762 638

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 1 554 789

UNIVERSITEIT ANTWERPEN

Belgium

EU Contribution

€ 6 926 603

UNIVERSITE DE GENEVE

Switzerland

EU Contribution

€ 4 957 467

JULIUS CLINICAL RESEARCH BV

Netherlands

EU Contribution

€ 1 567 067

UNIVERSITAETSKLINIKUM FREIBURG

Germany

EU Contribution

€ 331 368

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Switzerland

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

NORTH BRISTOL NATIONAL HEALTH SERVICE TRUST

United Kingdom

EU Contribution

€ 1 184 970

UNIVERSITE JOSEPH FOURIER GRENOBLE 1

France

EU Contribution

€ 5 918

GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.

United Kingdom

JANSSEN PHARMACEUTICA NV

Belgium

SERVICIO ANDALUZ DE SALUD

Spain

EU Contribution

€ 220 693

CHU de Pointe-à-Pitre

France

EU Contribution

€ 39 614

LINKOPINGS UNIVERSITET

Sweden

EU Contribution

€ 57 934

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON

Greece

EU Contribution

€ 57 934

EBERHARD KARLS UNIVERSITAET TUEBINGEN

Germany

EU Contribution

€ 1 018 710

UNIVERSITAET GREIFSWALD

Germany

EU Contribution

€ 870 128

UNIVERSITE LYON 1 CLAUDE BERNARD

France

EU Contribution

€ 858 140

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

EU Contribution

€ 1 136 553

CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

Spain

EU Contribution

€ 174 934

SERVICIO MADRILENO DE SALUD

Spain

EU Contribution

€ 228 934

THE FOUNDATION FOR MEDICAL RESEARCH INFRASTRUCTURAL DEVELOPMENT AND HEALTH SERVICES NEXT TO THE MEDICAL CENTER TEL AVIV

Israel

EU Contribution

€ 57 934

INSTITUTO NACIONAL DE SAUDE DR. RICARDO JORGE

Portugal

EU Contribution

€ 57 934

AO DOCUMENTATION AND PUBLISHING FOUNDATION

Switzerland

EU Contribution

€ 57 934

FONDAZIONE IRCCS CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO

Italy

EU Contribution

€ 57 934

ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK

France

UNIVERSITAT ZURICH

Switzerland

EU Contribution

€ 223 891

DA VOLTERRA SAS

France

The Medicines Company

United States

Project information

Grant agreement ID: 115523

Status

Ongoing project

  • Start date

    1 January 2013

  • End date

    28 February 2021

Funded under:

FP7-JTI

  • Overall budget:

    € 149 984 051

  • EU contribution

    € 109 433 010

Coordinated by:

ASTRAZENECA AB

Sweden